CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性 DLBCL 的新策略；在侵袭性淋巴瘤中导航免疫治疗时代
英文原题：Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
查看英文原题
Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫大B细胞淋巴瘤（DLBCL）是最常见的侵袭性非霍奇金淋巴瘤类型。联合化疗与免疫治疗可治愈该病，然而近三分之一的患者在接受标准一线治疗后会出现难治性疾病或复发（R/R）。在二线治疗中，适合的患者的标准治疗策略已沿用四分之一世纪，即大剂量化疗后行自体干细胞移植，但超过一半的患者采用此方法后仍为化疗难治性疾病。当前基于化疗的方法未能治愈的患者可能从免疫治疗中获益。目前已开发出几类免疫治疗，包括抗体药物偶联物、双特异性T细胞衔接抗体、免疫检查点抑制剂和CAR-T 细胞。在以下综述中，我们讨论R/R DLBCL患者目前可用的免疫治疗选择。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma. Combination chemotherapy with immunotherapy can be curative, however, nearly one-third of patients will have a disease that is refractory or will relapse (R/R) after standard first-line therapy. In second-line, the standard treatment strategy for fit patients has been high dose chemotherapy followed by autologous stem cell transplant for a quarter-century, however more than half of patients have chemotherapy-refractory disease with this approach.
The patients not cured with current chemotherapy-based approaches may benefit from immunotherapy. Several classes of immunotherapy have been developed including antibody-drug conjugates, bispecific T-cell engaging antibodies, immune checkpoint inhibitors and chimeric antigen receptor T-cells. In the following review, we discuss the currently available immunotherapeutic options for patients with R/R DLBCL.
论文信息
- 作者
- Gordon MJ、Sureda A、Westin JR
- 单位
- MD Anderson Cancer Center, University of Texas, Houston, TX, USA.United States
- 期刊
- Leukemia & lymphoma2022 Sep
- 原文标识
- PubMed 35549635 · DOI 10.1080/10428194.2022.2068007